Leishmania is an obligate intracellular pathogen that invades phagocytic host cells.
Approximately 30 different species of Phlebotomine sand flies can transmit this parasite …

Introduction: Leishmaniasis broadly manifests as visceral leishmaniasis (VL), cutaneous
leishmaniasis (CL) and mucocutaneous leishmaniasis. The treatment of leishmaniasis is …

Pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate,
have been used for more than half a century in the therapy of the parasitic disease …

Background Visceral leishmaniasis (VL or kala azar) is the most serious form of human
leishmaniasis, responsible for over 20,000 deaths annually, and post kala azar dermal …

Estimated worldwide incidence of tegumentary leishmaniasis (cutaneous leishmaniasis [CL]
and mucocutaneous leishmaniasis [MCL]) is over 1.5 million cases per year in 82 countries …

Leishmaniasis is a diverse group of clinical syndromes caused by protozoan parasites of the
genus Leishmania. The clinical manifestation of the disease varies from self-limiting …

A vaccine against different forms of leishmaniasis should be feasible considering the wealth
of information on genetics and biology of the parasite, clinical and experimental immunology …

First generation candidate vaccines against leishmaniasis, prepared using inactivated
whole parasites as their main ingredient, were considered as promising because of their …

Leishmania are protozoan parasites spread by a sandfly insect vector and causing a
spectrum of diseases collectively known as leishmaniasis. The disease is a significant …

Leishmaniasis is caused by protozoan Leishmania parasites that are transmitted through
female sandfly bites. The disease is predominantly endemic to the tropics and semi-tropics …